A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)

ClinicalTrials.gov ID: NCT05376176

Public ClinicalTrials.gov record NCT05376176. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) - PHANTOM Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase IIa study to assess efficacy and safety of STN1010904 ophthalmic suspension (0.03%, and 0.1 %), twice daily dosing when compared to Placebo in subjects diagnosed with Fuchs Endothelial Corneal Dystrophy (FECD). This study will consist of a Screening Period of up to 15 days and an 18-month Double-Masked Treatment Period, including 9 individual visits to the study site.

Study identification

NCT ID: NCT05376176
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Santen Inc.; Industry
Enrollment: 86 participants

Conditions and interventions

Conditions

Fuchs Endothelial Corneal Dystrophy

Interventions

Drug

Eligibility (public fields only)

Age range: 30 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 18, 2022
Primary completion: May 25, 2025
Completion: May 25, 2025
Last update posted: Aug 6, 2026

2022 – 2025

United States locations

U.S. sites: 11
U.S. states: 9
U.S. cities: 11

Facility	City	State	ZIP	Site status
Stein Eye Institution UCLA	Los Angeles	California	90095	—
Price Vision Group	Indianapolis	Indiana	46260	—
Johns Hopkins University	Baltimore	Maryland	21287	—
Mayo Clinic	Rochester	Minnesota	55905	—
Tauber Eye Center	Kansas City	Missouri	64111	—
Comprehensive Eye Care, Ltd	Washington	Missouri	63090	—
Metropolitan Eye Research and Surgery Center	Palisades Park	New Jersey	07650	—
Devers Eye Institute	Portland	Oregon	97210	—
Scott Christie and Associates	Cranberry Township	Pennsylvania	16066	—
UPMC	Pittsburgh	Pennsylvania	15213	—
Houston Eye Associates	Houston	Texas	77025-1697	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05376176, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 6, 2026 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05376176 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →